Home World News CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced... World News CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer By Ogkologos - August 14, 2025 792 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CT041-ST-01 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR A Combination of Oral Mezigdomide Plus Dexamethasone Shows Promising Efficacy in... September 28, 2023 FDA Grants Accelerated Approval to Lurbinectedin for Metastatic SCLC June 19, 2020 ESMO Congress 2024 Barcelona, Spain, 13-17 September September 3, 2024 Julia Louis-Dreyfus Talks About The Side Effects of Chemotherapy May 3, 2019 Load more HOT NEWS Apalutamide Plus ADT Demonstrates a Rapid, Deep, and Durable PSA Decline... Neoadjuvant Followed by Adjuvant Pembrolizumab Prolongs Event-Free Survival Compared to Adjuvant... HER2 Expression is a Determinant of Sensitivity to Trastuzumab Deruxtecan in... Study Advances Fertility Preservation Approach for Male Cancer Survivors
